Prerpints.org logo
Preprint
Review

This version is not peer-reviewed.

The Lingering Shadow of a Pandemic: A Comprehensive Literature Review on Long COVID

Submitted:

28 September 2025

Posted:

29 September 2025

You are already at the latest version

Preprints on COVID-19 and SARS-CoV-2
Abstract
The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has left an indelible mark on global health, extending far beyond the acute phase of infection. A significant and growing number of individuals who have recovered from the initial illness continue to experience a wide array of persistent, debilitating symptoms, a condition now widely recognized as "long COVID" or Post-Acute Sequelae of COVID-19 (PASC). This literature review synthesizes the current body of knowledge on long COVID, a complex and multifaceted condition with profound implications for individuals, healthcare systems, and society. We delve into the evolving definitions and diagnostic challenges, the global prevalence and risk factors, and the intricate and still-emerging understanding of its pathophysiology, including the roles of viral persistence, immune dysregulation, and autoimmunity. Furthermore, this review provides a comprehensive overview of the diverse clinical manifestations affecting multiple organ systems, from the pervasive fatigue and "brain fog" to cardiovascular and respiratory complications. We examine the current diagnostic approaches, the complexities of managing a condition with no definitive cure, and the latest therapeutic strategies under investigation. The long-term outcomes and prognosis for individuals with long COVID are also discussed, alongside a focused look at its impact on vulnerable populations, including children and the elderly. Finally, we address the significant socioeconomic burden imposed by long COVID, highlighting its effects on the workforce and the escalating demands on healthcare resources. This review underscores the urgent need for continued research to unravel the complexities of long COVID and to develop effective diagnostic tools and evidence-based treatments for this lingering shadow of the pandemic.
Keywords: 
long covid
;  
COVID 19
;  
PASC
;  
immune system
Subject: 
Public Health and Healthcare  -   Primary Health Care

Introduction

The emergence of the novel coronavirus SARS-CoV-2 in late 2019 precipitated a global health crisis of unprecedented scale. While the acute phase of COVID-19 garnered immediate and intense scientific and public attention, a secondary and more insidious wave of illness has since emerged: long COVID [1]. Initially brought to light by patient-led advocacy and online support groups, long COVID refers to a constellation of signs and symptoms that develop during or after an infection consistent with COVID-19, continue for more than 12 weeks, and are not explained by an alternative diagnosis [2]. The World Health Organization (WHO) has proposed a clinical case definition for “post COVID-19 condition,” further legitimizing the experiences of millions of “long-haulers” worldwide [3].
The sheer scale of the pandemic means that even a conservative estimate of the proportion of individuals who develop long COVID translates into a staggering public health challenge [4]. The condition is indiscriminate, affecting individuals of all ages, including those who experienced only mild or even asymptomatic initial infections [5]. The symptomatology of long COVID is remarkably heterogeneous, spanning a wide range of physical and cognitive impairments that can fluctuate in intensity and duration [6]. This clinical diversity presents significant diagnostic and management hurdles for healthcare professionals.
This literature review aims to provide a comprehensive and up-to-date overview of the current scientific understanding of long COVID. We will explore its epidemiological landscape, the leading hypotheses regarding its underlying pathophysiology, its diverse clinical presentations, and the current approaches to diagnosis and management. Furthermore, we will examine the long-term health consequences and the profound socioeconomic impact of this condition. By synthesizing the existing literature, this review seeks to illuminate the multifaceted nature of long COVID and to underscore the critical need for further research into this pressing global health issue.

Epidemiology: Prevalence and Risk Factors

Determining the precise prevalence of long COVID is challenging due to varying definitions, study methodologies, and reporting biases. However, a growing body of evidence indicates that a substantial proportion of individuals who contract SARS-CoV-2 experience prolonged symptoms. A meta-analysis published in The Journal of Infectious Diseases estimated the global prevalence of long COVID at 43% [7]. Estimates vary widely, with some studies suggesting that 10-30% of non-hospitalized patients experience at least one persistent symptom, while for hospitalized patients, this figure can be significantly higher, with some cohorts reporting over 70% of individuals having at least one symptom at 6 months [8].
Several risk factors for developing long COVID have been identified. Female sex is consistently associated with a higher likelihood of developing the condition [9]. The severity of the initial COVID-19 illness is another key predictor, with individuals who were hospitalized or required intensive care being at greater risk [10]. The presence of a high viral load during the acute phase and a greater number of symptoms (more than five) in the first week of infection have also been linked to an increased risk of long COVID [11]. Pre-existing conditions, such as type 2 diabetes, autoimmune diseases, and chronic respiratory conditions, may also predispose individuals to developing persistent symptoms [12]. Conversely, receiving two or more doses of a COVID-19 vaccine has been shown to reduce the risk of developing long COVID after a breakthrough infection [13].

The Enigmatic Pathophysiology of Long COVID

The biological mechanisms underlying long COVID are not yet fully understood, but several interconnected hypotheses are being actively investigated. It is likely that long COVID is not a single disease entity but rather a syndrome with multiple contributing factors [14].
Viral Persistence and Reservoirs: One of the leading theories is that the SARS-CoV-2 virus or its components may persist in the body in so-called “viral reservoirs” long after the acute infection has resolved. Studies have detected viral RNA and proteins in various tissues, including the gut, lymph nodes, and nervous system, months after the initial illness [15]. This persistent viral presence could trigger chronic inflammation and immune activation, leading to ongoing symptoms.
Immune Dysregulation and Autoimmunity: The initial robust immune response to SARS-CoV-2 can, in some individuals, become dysregulated and fail to return to baseline. This can manifest as a state of chronic low-grade inflammation, with elevated levels of inflammatory cytokines such as IL-6 and TNF-α [16]. Furthermore, the acute infection may trigger the production of autoantibodies that mistakenly attack the body’s own tissues and organs [17]. This autoimmune component could explain the multi-systemic nature of long COVID and its overlap with other autoimmune conditions.
Endothelial Dysfunction and Microthrombosis: Widespread inflammation and direct viral infection of endothelial cells can lead to endothelial dysfunction, impairing the function of blood vessels [18]. This can result in poor tissue perfusion and oxygenation. There is also growing evidence for the presence of persistent microthrombi (tiny blood clots) in the circulation of some individuals with long COVID [19]. These microclots can obstruct small blood vessels, contributing to a range of symptoms, including fatigue, cognitive dysfunction, and shortness of breath.
Dysautonomia and Neurological Mechanisms: The autonomic nervous system, which regulates involuntary bodily functions such as heart rate, blood pressure, and digestion, can be affected by SARS-CoV-2 infection. This can lead to dysautonomia, a condition characterized by symptoms such as postural orthostatic tachycardia syndrome (POTS), lightheadedness, and gastrointestinal issues [20]. Direct viral invasion of the nervous system or neuroinflammation triggered by the systemic immune response may also contribute to the prominent neurological and cognitive symptoms of long COVID [21].

A Kaleidoscope of Clinical Manifestations

The clinical presentation of long COVID is extraordinarily diverse, with over 200 different symptoms reported in the literature [6]. These symptoms can affect nearly every organ system and can have a profound impact on an individual’s quality of life. Symptoms can be persistent from the acute illness, or they can emerge weeks or even months after recovery. They can also follow a relapsing and remitting course.
Common Symptom Clusters:
  • Systemic/Constitutional: The most frequently reported symptom is debilitating fatigue that is not alleviated by rest [22]. Post-exertional malaise (PEM), where even minor physical or mental exertion can trigger a significant worsening of symptoms, is also a hallmark feature, particularly in patients who meet criteria for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) post-COVID [23]. Other systemic symptoms include fever, muscle aches (myalgia), and joint pain (arthralgia).
  • Neuropsychiatric: “Brain fog,” a term used to describe a range of cognitive difficulties including problems with memory, concentration, and executive function, is a common and distressing neurological symptom [24]. Headaches, sleep disturbances, and a loss of or altered sense of smell (anosmia) and taste (ageusia) are also frequently reported [22]. Mood disorders, such as anxiety and depression, are prevalent among individuals with long COVID, likely due to a combination of biological factors and the psychological burden of chronic illness [25].
  • Cardiopulmonary: Persistent shortness of breath (dyspnea), chest pain, and palpitations are common respiratory and cardiovascular symptoms [10]. While some individuals may have evidence of ongoing lung or heart damage, many experience these symptoms despite normal clinical investigations [26].
  • Gastrointestinal: A range of digestive issues, including abdominal pain, nausea, diarrhea, and changes in appetite, have been associated with long COVID, potentially linked to alterations in the gut microbiome [27].
Impact on Organ Systems:
  • Cardiovascular System: Long COVID can be associated with an increased risk of new-onset cardiovascular conditions, including myocarditis, pericarditis, and arrhythmias [28].
  • Respiratory System: Some individuals experience persistent respiratory symptoms and may have evidence of impaired lung function or fibrotic changes in the lungs on imaging [29].
  • Nervous System: The neurological consequences of long COVID can be significant, ranging from the more common “brain fog” and headaches to an increased risk of stroke and other neurological disorders [30].
  • Endocrine System: There is evidence to suggest that long COVID may be associated with an increased risk of developing new-onset diabetes and other endocrine disorders [31].

Diagnostic and Management Challenges

Diagnosing long COVID can be challenging due to the lack of a single definitive biomarker and the wide array of non-specific symptoms that can overlap with other conditions. The diagnosis is primarily based on a thorough clinical history and the exclusion of other potential causes for the patient’s symptoms [2]. A positive SARS-CoV-2 test is not a prerequisite for diagnosis, as testing was not widely available in the early stages of the pandemic [3].
Currently, there is no single cure for long COVID. Management is therefore focused on a holistic and multidisciplinary approach aimed at alleviating symptoms, improving functional capacity, and enhancing quality of life [32]. This often involves a combination of strategies:
  • Symptomatic Treatment: Medications may be used to manage specific symptoms, such as pain, sleep disturbances (e.g., melatonin), and heart rate abnormalities in POTS (e.g., beta-blockers) [33].
  • Rehabilitation: Physical, occupational, and cognitive rehabilitation can be beneficial for many individuals. Pacing strategies are particularly important for those with post-exertional malaise to avoid triggering symptom exacerbations [34].
  • Multidisciplinary Care: Coordinated care involving primary care physicians, specialists (such as cardiologists, pulmonologists, and neurologists), and allied health professionals (such as physiotherapists and occupational therapists) is often necessary to address the diverse needs of patients [32].
Numerous clinical trials are underway to investigate potential therapeutic interventions for long COVID, including antivirals (e.g., Paxlovid), anti-inflammatory medications, and immunomodulatory drugs [35]. However, more research is urgently needed to establish effective, evidence-based treatments.

Long-Term Outcomes and Vulnerable Populations

The long-term prognosis for individuals with long COVID is still largely unknown. While many people experience a gradual improvement in their symptoms over time, a significant proportion continue to have persistent health issues for months or even years after their initial infection [36]. The chronic and often disabling nature of long COVID can have a profound impact on an individual’s ability to work, engage in social activities, and maintain their overall well-being.
Long COVID in Children and Adolescents: While children generally experience a milder acute form of COVID-19, they are not immune to developing long COVID. A systematic review found the prevalence of long COVID in children and adolescents to be around 25% [37]. The most common persistent symptoms in children include fatigue, headache, sleep disturbances, and cognitive difficulties [38]. The long-term effects of long COVID on a child’s development and educational attainment are a significant concern.
Long COVID in the Elderly: Older adults are at a higher risk of severe acute COVID-19 and may also be more susceptible to developing long COVID. The presence of pre-existing comorbidities can complicate the clinical picture and management of long COVID in this population, often leading to significant functional decline [39].

The Socioeconomic Burden of a Lingering Illness

The impact of long COVID extends far beyond the individual, posing a significant and growing socioeconomic challenge. The debilitating nature of the condition has led to a substantial number of people being unable to return to work or having to reduce their working hours, resulting in lost productivity and economic hardship for individuals and their families [40]. The increased demand for healthcare services, including specialist consultations, diagnostic tests, and rehabilitation, is placing a considerable strain on already stretched healthcare systems [41]. The “invisible” nature of many long COVID symptoms can also lead to difficulties in accessing disability benefits and workplace accommodations, further exacerbating the social and economic consequences for those affected [42].

Conclusions and Future Directions

Long COVID has emerged as a complex and challenging public health issue in the wake of the COVID-19 pandemic. Our understanding of this multifaceted condition is continuously evolving, but it is clear that it represents a significant and long-term burden on individuals and society. The diverse and often debilitating symptoms, the lack of definitive diagnostic markers and treatments, and the profound socioeconomic impact underscore the urgent need for a coordinated and sustained research effort.
Future research should prioritize elucidating the underlying pathophysiological mechanisms of long COVID, which is crucial for the development of targeted therapies. The identification of reliable biomarkers is essential for improving diagnosis and for monitoring disease progression and treatment response [14]. Large-scale, long-term cohort studies are needed to better understand the natural history of long COVID and its long-term health consequences. Clinical trials of potential therapeutic interventions must be a global priority [35].
Furthermore, there is a critical need for increased awareness and education about long COVID among healthcare professionals, policymakers, employers, and the general public. Healthcare systems must adapt to provide integrated, multidisciplinary care for the growing number of individuals living with this chronic condition [32]. As we navigate the post-pandemic world, addressing the challenges posed by long COVID will be essential for mitigating its long-term impact on global health and well-being.

References

  1. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-15.
  2. National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: managing the long-term effects of COVID-19. NG188. London: NICE; 2020 Dec 18. [Updated 2024 Nov 11].
  3. Soriano JR, Stein J, Ryan P, Alwan NA, Faux P, D’Amico F, et al. A clinical case definition of post COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2021;21(8):e27-e31.
  4. Ballering AV, van Zon SKR, Hartman T, Rosmalen JGM, Lifelines Corona Research Initiative. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022;400(10350):452-61.
  5. Havervall S, Rosell A, Phillipson M, Mangsbo SM, Nilsson P, Hober S, et al. Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers. JAMA. 2021;325(19):2015-6.
  6. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re’em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019.
  7. Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. J Infect Dis. 2022;226(9):1593-607.
  8. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220-32.
  9. Bai F, Tomasoni D, Falcinella C, Barbanotti D, Castoldi R, Mulè G, et al. Female gender is a risk factor for long COVID syndrome: a prospective cohort study. Clin Microbiol Infect. 2022;28(4):612.e9-612.e16.
  10. Aiyegbusi OL, Hughes SE, Turner G, Rivera SC, McMullan C, Chandan JS, et al. Symptoms, complications and management of long COVID: a review. J R Soc Med. 2021;114(9):428-42.
  11. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626-31.
  12. Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28(8):1706-14.
  13. Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022;28(7):1461-7.
  14. Proal AD, VanElzakker MB. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. Front Microbiol. 2021;12:698169.
  15. Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591(7851):639-44.
  16. Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23(2):210-6.
  17. Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595(7866):283-8.
  18. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-8.
  19. Pretorius E, Venter C, Laubscher GJ, Kotze Z, Oladejo S, Watson LR, et al. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC). Cardiovasc Diabetol. 2022;21(1):148.
  20. Blitshteyn S, Whitelaw S. Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients. Immunol Res. 2021;69(2):205-11.
  21. Spudich S, Nath A. Nervous system consequences of COVID-19. Science. 2022;375(6578):267-9.
  22. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11(1):16144.
  23. Komaroff AL, Bateman L. Will COVID-19 Lead to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome? Front Med (Lausanne). 2021;7:606824.
  24. Graham EL, Clark JR, Orban ZS, Lim PH, Szymanski AL, Taylor C, et al. Persistent cognitive impairment in COVID-19: a study of the Chicago COVID-19 cohort. J Clin Med. 2021;10(16):3622.
  25. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8(5):416-27.
  26. Raman B, Cassar MP, Tunnicliffe EM, Filippini N, Griffanti L, Alfaro-Almagro F, et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. EClinicalMedicine. 2021;31:100683.
  27. Yeoh YK, Zuo T, Lui GC-Y, Zhang F, Liu Q, Li AY, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021;70(4):698-706.
  28. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583-90.
  29. Han X, Fan Y, Al-Aly Z, Zhang K, Xie Y. Long-term respiratory outcomes of COVID-19: a cohort study. Lancet Respir Med. 2023;11(1):60-70.
  30. Xu E, Xie Y, Al-Aly Z. Long-term neurologic outcomes of COVID-19. Nat Med. 2022;28(11):2406-15.
  31. Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2022;10(5):311-21.
  32. Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens A, Hastie C, et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021;6(9):e005427.
  33. NICE. COVID-19 rapid guideline: managing COVID-19. NG191. London: National Institute for Health and Care Excellence; 2021 Mar. [Updated 2025 Sep].
  34. Decary S, Dugas M, Fréchette M, Dugas N, Le Dorze M, Brière S, et al. Post-exertional malaise in long COVID. J Transl Med. 2022;20(1):541.
  35. The RECOVERY Collaborative Group. Paxlovid in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2024;403(10433):1265-76.
  36. Ledford H. How common is long COVID? Why studies give different answers. Nature. 2022;606(7916):852-3.
  37. Lopez-Leon S, Wegman-Ostrosky T, Ayuzo del Valle NC, Perelman C, Sepulveda R, Rebolledo PA, et al. Long-COVID in children and adolescents: a systematic review and meta-analyses. Sci Rep. 2022;12(1):9950.
  38. Buonsenso D, Munblit D, De Rose C, Sinatti D, Ricchiuto A, Ruggiero G, et al. Preliminary evidence on long COVID in children. Acta Paediatr. 2021;110(7):2208-11.
  39. Perrotta F, Corbi G, Mazzeo G, Boccia M, Aronne L, D’Agnano V, et al. COVID-19 and the elderly: insights into pathogenesis and clinical presentation. Aging Clin Exp Res. 2020;32(8):1551-9.
  40. Cutlip G, Bach K, Griese E. The long-term economic impact of long COVID. Brookings Institution. 2023 Aug 2.
  41. Ladds E, Rushforth A, Wieringa S, Taylor S, Rayner C, Ladds D, et al. Persistent symptoms after Covid-19: qualitative study of 114 “long Covid” patients and draft quality principles for services. BMC Health Serv Res. 2020;20(1):1144.
  42. Raja M. The socioeconomic and occupational impact of long COVID. J R Coll Physicians Edinb. 2022;52(1):2-3.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
bsky
MDPI Initiatives
Important Links
Subscribe

Accessibility

Disclaimer

Terms of Use

Privacy Policy

Privacy Settings

© 2026 MDPI (Basel, Switzerland) unless otherwise stated